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Abstract
Arginine vasopressin (AVP) and corticotropin-releasing hor-
mone (CRH) have both been implicated in modulating insulin
secretion from pancreatic b-cells. In the present study, we
investigated the insulin-secreting activities of AVPand CRH in
wild-type and AVP VIb receptor knockout mice. Both
neuropeptides stimulated insulin secretion from isolated mouse
pancreatic islets. The response of islets to CRH was increased
fourfoldbyconcomitantincubationwithasubthresholddoseof
AVPthatalonedidnotstimulateinsulinsecretion.Activationof
the endogenously expressed M3 receptor by the cholinergic
agonist carbachol also potentiated CRH-induced insulin
secretion, indicating that the phenomenon may be pathway
speciﬁc(i.e.Ca
2C-phospholipaseC)ratherthanagonistspeciﬁc.
The protein kinase C (PKC) inhibitors Ro-31-8425 and
bisindolylmaleimide I attenuated the potentiating effect of
AVP on CRH-stimulated insulin secretion and blocked
AVP-stimulated insulin secretion. A possible interaction
between the PKC and protein kinase A pathways was also
investigated.Thephorbolesterphorbolmyristateacetate(PMA)
stimulated insulin secretion, while the addition of both PMA
and CRH enhanced insulin secretion over that measured with
either PMA or CRH alone. Additionally, no AVP potentiation
of CRH-stimulated insulin secretion was observed upon
incubation in Ca
2C-free Krebs–Ringer buffer. Taken together,
thepresentstudysuggestsapossiblesynergismbetweenAVPand
CRHtoreleaseinsulinfrompancreaticb-cellsthatreliesatleast
in part on activation of the PKC signaling pathway and is
dependent on extracellular Ca
2C. This is the ﬁrst example of a
possibleinterplaybetweentheAVPandCRHsystemsoutsideof
the hypothalamic–pituitary–adrenal axis.
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Introduction
Themainfunctionofthepancreaticb-cellistosecreteinsulinto
maintain glucose homeostasis. Insulin secretion is a complex
process that is primarily regulated by the levels of circulating
glucose and is ﬁne-tuned by additional factors such as other
nutrients (e.g., amino acids) and growth factors, as well as by
intra-isletautocrineandparacrineinteractions.Thestimulatory
effectsofglucoseoninsulinsecretionaremediatedbychangesin
intracellular Ca
2C levels and are modulated by signals
generated by neurotransmitter and hormone binding to G
protein-coupled receptors (GPCR) present on islet b-cells
(Lang 1999, Henquin 2000, Ahren et al.2 0 0 6 ). Several GPCR
agonists including norepinephrine, dopamine, galanin, and
apelin inhibit insulin secretion following binding to pertussis
toxin-sensitive Gi/o-coupled receptors (Lang 1999, Rubi et al.
2005, Sorhede Winzell et al.2 0 0 5 , Ahren et al.2 0 0 6 ). On the
otherhand,neurotransmittersandhormoneslikeacetylcholine,
angiotensin II, and cholecystokinin act on their receptors via
coupling to the G protein Gq/11 to potentiate glucose-induced
insulin secretion by promoting phosphoinositide hydrolysis
with a consequent increase in inositol 1,4,5-trisphosphate
(InsP3) production, elevation of intracellular Ca
2C, and
activation of protein kinase C (PKC; Lang 1999, Ahren et al.
2006, Ramracheya et al.2 0 0 6 ). Other potentiators, such as the
incretin hormones, glucagon-like peptide 1 and glucose-
dependent insulinotropic polypeptide, and pituitary adenylate
cyclase-activating protein and glucagon, stimulate adenylate
cyclase and increase cAMP levels via an interaction with the
stimulatoryGproteinGsandactivatecAMP-dependentprotein
kinaseA(PKA;Lang1999).Thereisconsiderableevidencethat
cAMP/PKA directlyor indirectly regulates components of the
Ca
2C-signaling system including InsP3 generation, InsP3
receptors, plasma membrane Ca
2C-ATPase, and L-type Ca
2C
channels (Henquin et al.1 9 8 7 , Lang 1999, Henquin 2000,
Bruce et al.2 0 0 3 ). A feature of stimulus-secretion coupling in
b-cells is this intracellular cross talk, where compounds that
activate PKC and PKA act synergistically to enhance insulin
secretion (Henquin et al.1 9 8 7 , Henquin 2000).
The hypothalamic neuropeptide corticotropin-releasing
hormone(CRH)playsacentralroleinthemammalianresponse
to stress and exerts a wide range of roles in the brain (e.g.,
mediating anxiety behavior) and peripheral tissues (e.g., female
reproductive tract; Bale & Vale 2004, Kalantaridou et al.2 0 0 4 ).
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Ucn III, elicit their effects by binding to two GPCRs, CRH-
type 1 and 2 receptors (CRHR1 and CRHR2), which
primarily stimulate the adenylate cyclase/cAMP second
messenger system (Hillhouse & Grammatopoulos 2006).
CRHR1andCRHR2arewidelydistributedandhaverecently
been demonstrated in rodent pancreas islets by immunocyto-
chemistry (Kanno et al.1 9 9 9 ). In addition, Ucn III is expressed
in mouse b-cells suggesting that the CRH system may be
involved in the local regulation of pancreatic endocrine
secretions (Li et al.2 0 0 3 ). Indeed, accumulating evidence
suggeststhattheCRHfamilyofpeptidesstimulateCa
2Cinﬂux
intoisolated isletsandenhanceinsulin releasein the presence of
glucose(Kannoetal.19 99 ,Li etal.20 03 ,Kageyamaet al.20 06 ).
CRH is a major regulator of the hypothalamic–pituitary–
adrenal (HPA) axis under basal and stressful conditions (Bale
& Vale 2004). It rapidly stimulates adrenocorticotropin
(ACTH) secretion by binding to the CRHR1 on pituitary
corticotropes. This action is potentiated by the neurohypo-
physeal hormone arginine vasopressin (AVP) that has modest
effects on ACTH release acting by itself (Gillies et al. 1982,
Vale et al. 1983). The CRH-potentiating role of AVP in the
anterior pituitary is mediated through the Gq/11-coupled
AVP V1b receptor (AVPR1b) and is PKC dependent
(Abou-Samra et al. 1986, Lolait et al. 1995). The AVPR1b
is also expressed in extra-pituitary sites, principally the brain,
adrenal, and pancreas (Lolait et al. 1995, Saito et al. 1995).
Extensive studies have shown that AVP causes a PKC-
dependent rise in intracellular Ca
2C and potentiates glucose-
induced insulin release from insulin-secreting cell lines and
isolated b-islets (see Gao et al 1990, 1994, Lee et al. 1995,
Schaeffer et al. 2004). Moreover, in one study immuno-
reactive AVP (and the related nonapeptide oxytocin) was
found in the rat and human pancreas, suggesting that like
CRH, AVP may play a local regulatory role in pancreatic
function (Amico et al. 1988). More recently pharmacological
and gene knockout studies have unequivocally demonstrated
that AVP-stimulated insulin release from b-islets is mediated
by the AVPR1b (Folny et al. 2003, Oshikawa et al. 2004).
In the present study, we hypothesized that AVP and CRH
act synergistically to release insulin from pancreatic b-cells.
We show that AVP potentiates CRH-induced insulin
secretion from isolated mouse islets at a dose at which AVP
alone has no effect on insulin secretion, suggesting a
synergism between these two peptides that is involved in
paracrine or autocrine stimulation of insulin secretion.
Materials and Methods
Animals
Adult male (12–16 weeks) mice (a mix of the C57BL/6J and
129X1/SvJ strains) were group housed (three to four per
cage) under controlled light and temperature (21G2 8C)
with food and water available ad libitum and maintained on a
14 h light:10 h darkness cycle (lights on at 0500 h). Mice
deﬁcient for the AVPR1b were generated from crosses using
mice heterozygous for the AVPR1b mutation (Wersinger
et al. 2002), identiﬁed by PCR analysis of DNA isolated
from tail clips. Studies were performed between 0900 and
1200 h. All procedures were conducted in accordance with
the Animal Scientiﬁc Procedures Act (1986) United King-
dom and the appropriate University of Bristol Ethical
Review Process.
Pancreatic islet isolation and insulin assay
Pancreatic islets were isolated from mice by collagenase (NB8
Serva GmbH/AMS Biotechnology Abingdon, Oxfordshire,
UK) digestion and subsequent centrifugation in a Histopaque
(1083-1, 1077-1, 1119-1 Sigma) gradient. Brieﬂy, mice were
killed by cervical dislocation and medium (RPMI 1640
(Gibco), 1% Pen/Strep, 1.1% glucose (RPMIK); 2.5 ml) was
injected into the pancreas. The swollen pancreas was
surgically removed, cut into small pieces in RPMIK medium
containing collagenase (0.5 mg/ml), incubated at 37 8C
for 17 min, and digestion terminated by adding 10 ml
ice-cold RPMI medium containing 10% fetal bovine serum
( RPMIC). Digested pancreata were then ﬁltered through a
sieve, washed twice in RPMIK medium, and resuspended in
a5 mllayerofHistopaque1119-1andoverlaidwithsuccessive
5 ml layers of Histopaque 1083-1, Histopaque 1077-1, and
RPMIK medium. The sample was centrifuged at 863 g for
20 min at 4 8C. Islets were collected from the interface and
resuspended in RPMIC medium and cultured overnight at
37 8C at 95% O2/5% CO2.
Following culture, islets were washed twice with Krebs–
Ringer buffer (KRB; 2.5m MC a C l 2,5 .4m MK C l ,0 .8m M
MgSO4, 116 mM NaCl, 20 mM NaHCO3,0 .9m M
NaH2PO4) containing 10 mM HEPES, 1% BSA, and
2.8 mM glucose, and preincubated in the same buffer for
60 min at 95% O2/5% CO2.I s l e t sw e r eh a n d p i c k e du n d e ra
microscope and batches of ﬁve were then transferred to
borosilicate tubes and incubated, in triplicate, at 37 8C with
testing agents diluted in KRB containing 10 mM HEPES, 1%
BSA, and 10 mM glucosefor a further 60 min. For incubations
with antagonists, islets were pretreated with antagonist for
15 min followed by incubation with testing agents for a further
60 min. The incubation was terminated by brief centrifugation
and the supernatants collected and stored at K20 8Cu n t i la s s a y
for insulin by ELISA (Diagenics Ltd, Milton Keynes, UK).
ELISA was performed according to the manufacturer’s
instructions and analyzed using a microplate reader (Microplate
5.1, Bio-Rad Laboratories). Experiments on the effects of
extracellular Ca
2C were performed in Ca
2C-free KRB
supplemented with 1 mmol/l EGTA. The PKC inhibitors
Ro-31-8425 (2-[8-(aminomethyl)-6,7,8,9-tetrahydropyr-
ido[1,2-a]indol-3-yl]-3-(1-methyl-1H-indol-3-yl)maleimide,
HCl) and bisindolylmaleimide I (2-[1-(3-dimethyl-
aminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide),
phorbol-12-myristate-13-acetate (PMA), and 4a-phorbol
A-MO ’CARROLL and others . AVP potentiates CRH-induced insulin release 232
Journal of Endocrinology (2008) 197, 231–239 www.endocrinology-journals.org(4a,9a,12b,13a,20-pentahydroxytigilia-1,6-dien-3-one) were
obtainedfromMerckChemicalsLtd.Carbacholandastressin2-B
(triﬂuoroacetate salt) were obtained from Sigma–Aldrich.
Statistical analysis
AllvalueswereexpressedasmeansGS.E.M.andpresentedasthe
mean percentage change from control, assigned an arbitrary
value of 100. Results were analyzed using one-way ANOVA
followed by Newman–Keuls multiple comparison post hoc
test using GraphPad Prism(version 4.0b) software(San Diego,
CA, USA). P!0.05 was considered statistically signiﬁcant.
Results
Stimulation of insulin secretion from pancreatic islets by AVP
and CRH
Mouse pancreatic islets were isolated and the absolute levels of
insulin secreted in the presence of 2.8m Mg l u c o s e ,1 0m M
glucose,and56 mMKClweredeterminedtobe0.586G0.003,
1.1G0.1,and8.18G2.43 ng/ml per hper isletrespectively. As
AVPstimulationofglucose-inducedinsulinsecretioniseffective
only at glucose levels above 7 mM (Gao et al.1 9 9 0 ), islets were
incubatedin10 mMglucoseforexperimentalprocedures.Both
AVPand CRH caused a signiﬁcant dose-dependent increase in
insulin secretion from wild-type mouse pancreatic islets in the
presenceof10 mMglucose.AVPstimulatedinsulinsecretionin
the dose rangefrom0.25to100 nM(Fig.1A)while CRH, ata
relatively high dose (50 nM), also stimulated insulin secretion
(Fig.1B).RecentstudiesindicateanimportantroleforUcnIII,
acting through CRHR2, in insulin secretion from rat islets (Li
et al. 2003, 2006). However, in our system, Ucn III failed to
stimulate insulin secretion at any dose tested (Fig. 1B). To
determine whether endogenous Ucn III contributes to the
effect mediated by CRH, mouse islets were incubated with
100 nMCRHandtheCRHR2-selectiveantagonistastressin2-
B(Ast 2-B).Pretreatmentwith1 mMAst 2-Bhadnoef fectonthe
stimulatory effect of CRH on insulin release (Fig. 2).
Potentiation of CRH-induced insulin secretion from pancreatic
islets by AVP
To investigatean interactionbetween AVPandCRH ininsulin
secretion, isolated mouse islets were incubated with 100 nM
CRH, a dose at which this peptide was shown to stimulate
insulin release, either alone or in combination with a range of
AVP doses (0.05–100 nM). Concomitant incubation of CRH
with doses of AVP shown to stimulate insulin secretion when
given alone (0.25–100 nM) did not further increase insulin
secretion above that seen with either AVP or CRH alone
(Fig.3).However,incubationofCRHwithsubthresholddoses
of AVP (0.05 and 0.1 nM), doses at which AVP alone did not
stimulate insulin secretion, induced a signiﬁcant enhancement
of insulin secretion when compared with CRH or AVP
treatment alone (Figs 3 and 4A). Concomitant incubation of
0.05–0.1 nM AVP with 100 nM CRH increased CRH-
induced insulin secretion approximately threefold.
Effects of muscarinic receptor activation on CRH-induced insulin
secretion
AVP causes a PKC-dependent rise in intracellular Ca
2C and
potentiates glucose-induced insulin release from insulin-
secreting cell lines and isolated b-islets (Gao et al. 1990,
Figure 1 Dose–response curves of (A) AVPand (B) CRH and Ucn III
on insulin secretion from isolated mouse pancreatic islets. (A) AVP
and (B) CRH (C) and Ucn III (,) at the indicated doses were
incubated with isolated pancreatic islets (batches ofﬁve) for 60 min
in the presence of 10 mM glucose. Insulin secreted is represented as
the percentage of insulin secretedin the presence of 10 mM glucose
whose value was set as 100%. The level of insulin secreted was
determined byELISA.Values represent meanGS.E.M. ofat least three
different experiments in triplicate.
AVP potentiates CRH-induced insulin release . A-MO ’CARROLL and others 233
www.endocrinology-journals.org Journal of Endocrinology (2008) 197, 231–2391994, Lee et al. 1995, Schaeffer et al. 2004). To determine
whether the potentiation of CRH-induced insulin secretion
by AVP is speciﬁc for AVP alone or is also characteristic of
other PKC activators, the interaction between CRH and the
cholinergic agonist carbachol (CCh) in insulin secretion was
investigated. CCh primarily activates the M3 muscarinic
receptor to enhance insulin secretion from b-cells (Zawalich
et al. 2004). CCh, at doses of 1 nM and above, stimulated
insulin secretion (data not shown) from in vitro mouse islets.
Incubation of subthreshold doses of CCh (0.1 nM) with
CRH (100 nM) increased CRH-induced insulin secretion
over twofold (Fig. 4B), indicating that the potentiation of
CRH-induced insulin secretion may be the result of
activation of the Ca
2C-phospholipase C-signaling pathway.
Effect of PKC inhibition on AVP potentiation
of CRH-stimulated insulin secretion
To investigate whether the AVP potentiation of CRH-
stimulated insulin secretion may be mediated by PKC
activation, isolated mouse islets were incubated in the presence
ofPKCinhibitorsRo-31-8425andbisindolylmaleimideI(Bis).
Ro-31-8425 is a potent and selective PKC inhibitor, which
exhibits slight selectivityfor PKCa,P K C b, and PKCg over the
Ca
2C-independent PKC isoenzyme PKC3, whereas Bis shows
highselectivityforPKCa-,bI-,bII-,g-,d-,and3-isozymes.As
shown in Fig. 5A, incubation with either Ro-31-8425 or Bis
attenuated the potentiating effect of AVP on CRH-induced
insulin secretiontoa level ofsecretionseenwith100 nMCRH
alone, while AVP (100 nM)-induced insulin secretion was
reduced tobasallevels. Incubation withthe PKCinhibitors had
no effect on insulin secretion induced by 100 nM CRH
(Fig. 5A) probably owing to cellular signaling that is largely
independent of PKC activation.
Stimulation of insulin secretion from pancreatic islets by PMA
To investigate the interaction between the PKC and PKA
signalingpathwaysintheAVPpotentiationofCRH-stimulated
insulin secretion, isolated mouse islets were incubated with
100 nM CRH, a dose at which this peptide was shown to
stimulate insulin release, either alone or in combination with a
rangeofPMAdoses(0.01–1 nM).PMAalonestimulatedinsulin
secretionwhileconcomitantincubationwithCRHpotentiated
insulin secretion over that measured after the addition of either
PMA or CRH given alone; however, signiﬁcance was only
achieved with the addition of lower doses of PMA with CRH
(Fig.5B).NoinsulinsecretionorpotentiationofCRH-induced
insulin secretion was seen after incubation with the inactive
phorbol compound, 4-a-phorbol (0.01 and 1 nM).
Effect of extracellular Ca
2C on the stimulation of insulin secretion
from pancreatic islets
The dependence of the observed interplay between AVP and
CRHonextracellularCa
2Cwasexamined.Isolatedmouseislets
were incubated either in KRB or in Ca
2C-free KRB, with
either 0.1 nM AVP, a dose at which this peptide does not
stimulate insulin release, 100 nMCRH, or bothagonistsadded
Figure 2 Effects of Ast2-B on CRH-induced insulin secretion from
isolated mouse pancreatic islets. Agonists at the indicated doses
were incubatedwith isolated islets (batches ofﬁve) for 60 min in the
presence of 10 mM glucose. CRH (100 nM) stimulated insulin
secretion in the presence of 10 mM glucose. Pretreatment with
1 mM Ast2-B had no effect on CRH-induced insulin secretion. Paired
t-tests showed no signiﬁcant difference between CRH and CRHC
Ast2-B levels of insulin secretion and between Ast2-B and basal
levels of insulin secretion. Insulin secreted is represented as the
percentage of insulin secreted in the presence of 10 mM glucose
whose value was set as 100%. Values represent meanGS.E.M.o fa t
least three different experiments in triplicate.
Figure 3 Effects of AVP and CRH interaction on insulin secretion
from isolated mouse pancreatic islets. Insulin secretion after
incubation of isolated islets (batches of ﬁve) for 60 min in the
presence of 10 mM glucose with the indicated doses of AVPand/or
CRH. Concomitant incubation of 100 nM CRH with doses of AVP
shown to stimulate insulin secretion alone (0.25–100 nM) showed
no signiﬁcant increase in insulin secretion above that seen with
either peptide alone. Incubation of 100 nM CRH with either
0.05 nM or 0.1 nM AVP, doses at which AVP does not stimulate
insulin secretion, induced a signiﬁcant enhancement of insulin
secretion when compared with CRH treatment alone. Insulin
secreted is represented as the percentage of insulin secreted in the
presence of 10 mM glucose whose value was set as 100%. Values
represent meanGS.E.M. of at least three different experiments in
triplicate. ***P!0.001 indicates signiﬁcant differences from islets
treated with 100 nM CRH, 0.05 nM AVP, or 0.1 nM AVP alone.
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(100 nM) in KRB increased CRH-induced insulin secretion
approximately threefold (Fig. 6), whereas no potentiation was
observed upon incubation in Ca
2C-free KRB, suggesting that
the potentiation effect of AVP was absolutely dependent on
Ca
2C inﬂux from the extracellular space.
Stimulation of insulin secretion from pancreatic islets isolated
from AVPR1b KO mice
Pancreatic islets isolated from AVPR1b knockout (KO) mice
wereusedtoexaminetheeffectofdeletingtheAVPR1bonAVP
potentiation of CRH-induced insulin secretion. In AVPR1b
KO mice, AVP-stimulated insulin secretion was completely
absent (Fig. 7A) and AVP failed to potentiate CRH-induced
insulin secretion (Fig. 7B).
Figure 4 Effects of AVP and carbachol (CCh) on CRH-induced
insulin secretion from isolated mouse pancreatic islets. (A) AVP
(0.1 nM) and CRH (100 nM) and (B) CCh (0.1 nM) and CRH
(100 nM) were incubated, either alone or together, with isolated
islets for 60 min. Incubation with a subthreshold dose of (A) AVP
alone and (B) CCh alone failed to stimulate insulin secretion.
Concomitant incubation of peptides induced a signiﬁcant poten-
tiation of (A) CRH-induced insulin secretion by AVP and (B) CRH-
induced insulin secretion by CCh. Insulin secreted is represented as
the percentage of insulin secreted in the presence of 10 mM glucose
whose value was set as 100%. Values represent meanGS.E.M.o fa t
least three different experiments in triplicate. ***P!0.001 indicates
signiﬁcant differences from islets treated with single peptide.
Figure 5 Effects of (A) PKC inhibitors Ro-31-8425 and bisindolylma-
leimide I and (B) PMA on AVP- and CRH-induced insulin secretion
from isolated mouse pancreatic islets. (A) Incubation with AVP
(100 nM) or CRH (100 nM) alone stimulated insulin secretion,
whereas incubation with AVP (0.1n M )d i dn o ts t i m u l a t ei n s u l i n
secretion. Concomitant incubation of isolated islets with AVP
(0.1 nM) and CRH (100 nM) induced a signiﬁcant enhancement of
insulinsecretion.Pretreatmentwith200 nMRo-31-8425(Ro)or2 mM
bisindolylmaleimide I (Bis) for 15 min before stimulation with testing
agents for 60 min attenuated the effect of 0.1 nM AVPon CRH-
induced insulin secretion and abolished the effect of 100 nM AVPon
AVP-inducedinsulinsecretion.Pretreatmentwitheitherinhibitorhad
no effect on 100 nM CRH-induced insulin secretion. ***P!0.001
indicatessigniﬁcantdifferencesofconcomitantincubationof100 nM
CRH and 0.1 nM AVP from islets treated with 100 nM CRH alone;
**P!0.01 indicates concomitant incubation of 100 nM CRH and
0.1 nMAVPfromCRH/AVP/Ro-31-8425andfromCRH/AVP/Bis;and
*P!0.05indicatesincubationof100 nMAVPfromAVP/Ro-31-8425
and from AVP/Bis. (B) PMA alone stimulated insulin secretion while
concomitant incubation with CRH potentiated insulin secretion over
thatmeasuredaftertheadditionofeitherPMAorCRHgivenalone.No
insulinsecretionorpotentiationofCRH-inducedinsulinsecretionwas
seen after incubation with the inactive phorbol compound, 4-a-
phorbol. Insulin secreted is represented as the percentage of insulin
secreted in the presence of 10 mM glucose whose value was set as
100%. Values represent meanGS.E.M. of at least three different
experiments in triplicate. ***P!0.001 indicates signiﬁcant
differences of concomitant incubation of 100 nM CRH and 0.01 nM
PMA from islets treated with 100 nM CRH or 0.01 nM PMA alone.
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The secretion of insulin is under complex control and intra-
islet feedback mechanisms exist to ensure proper levels of
insulin under given glycemic conditions. AVPand CRH have
both been implicated in modulating insulin secretion from
the endocrine pancreas and the clonal b-cell line, RINm5F
(Gao et al. 1990, Kanno et al. 1999, Lee et al. 1995).
WhileAVPhasbeenshowntoworkasapositivemodulatorof
glucose-stimulated insulin release by regulating plasma mem-
brane depolarization and the CD38-cyclic ADP ribose signal
system (Okamoto & Takasawa 2002), the role of AVP in the
regulationofinsulinreleasefromtheendocrinepancreasandthe
AVP receptor subtypes responsible for this modulation have
only recently been determined. Using a combined pharma-
cological and knockout approach, Oshikawa and coworkers
have clearly demonstrated that the AVP-stimulated insulin
release from the pancreatic b-cells is mediated via the AVPR1b
(Oshikawaetal.2004).Intheratpancreas,CRH,actingthrough
CRH receptors present on isolated b-cells, appears to have
stimulatoryeffectsoninsulinsecretion(Kannoetal.1999),while
the related peptide Ucn III has also been reported to regulate
insulin secretion, most likely via CRHR2, in rat pancreatic
b-cells (Li et al.2 0 0 3 ). In this study, we show for the ﬁrst time,
toourknowledge,thatCRHinducesinsulinsecretioninmouse
pancreatic b-cells and conﬁrm that AVP stimulates insulin
secretion from pancreatic islets isolated from wild-type control
mice, concurring with previous studies (Gao et al.1 9 9 0 ,
Oshikawaetal.20 04 ).CRHstimulatedinsulinsecretiononlyat
Figure 6 Effect of extracellular Ca
2C on the stimulation of insulin
secretion from isolated mouse pancreatic islets. Isolated mouse
pancreatic islets were incubated for 60 min either in KRB or in
Ca
2C-free KRB, with either 0.1 nM AVP, 100 nM CRH, or both
agonists added together. In KRB, CRH stimulated insulin secretion
and concomitant incubation with AVP increased the CRH-induced
insulin secretion approximately threefold. In Ca
2C-free KRB, no
stimulation of insulin secretion was observed upon incubation with
AVP, CRH, or both agonists added together. ***P!0.001 indicates
signiﬁcant differences from islets treated with 100 nM CRH or
0.1 nM AVP alone.
Figure 7 AVP-induced insulin secretion in mouse pancreatic islets
isolated from wild-type and AVPR1b KO mice. (A) AVP (100 nM)
inducedinsulinsecretioninpancreaticisletsisolatedfromwild-type
(WT)mice.InisletsisolatedfromAVPR1bKOmice,AVP-stimulated
insulin secretion was completely abolished. (B) Concomitant
incubation of 0.1 nM AVPand 100 nM CRH for 60 min with
pancreatic islets isolated from AVPR1b KO mice failed to produce
the potentiation of CRH-induced insulin secretion seen in the WT
mouse. Insulin secreted is represented as the percentage of insulin
secreted in the presence of 10 mM glucose whose value was set as
100%. Values represent meanGS.E.M. of at least three different
experiments in triplicate. ***P!0.001 indicates signiﬁcant
differencesfromwild-typemouseisletsandconcomitantincubation
of 100 nM CRH and 0.1 nM AVP from 100 nM CRH alone in
wild-type mouse islets.
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therat(Lietal.2003),whereasAVPappearstobemoreeffective
with signiﬁcant secretion being seen at 0.25 nM. This low
efﬁcacy of CRH in inducing insulin secretion appears to be a
limiting effect of the pancreatic CRH system as high
concentrations of the peptide are required to induce insulin
secretionatbothhigh(10 mM)andlow(2.8 mM)glucoselevels
in the rat (Li et al.2 0 0 3 ). These stimulatory effects of CRH
appeartobeactingthroughtheCRHR1,aspreincubationwith
a selective CRHR2 antagonist, astressin2-B, failed to block the
observed induced insulin secretion. CRH has been reported to
be less potent than Ucn III, a high-afﬁnity ligand for the
CRHR2,instimulating insulinsecretion fromisolated rat islets
(Lietal.2003).Bycontrast,wedidnotobserveinsulinsecretion
induced by Ucn III from mouse islets, thus reinforcing the
suggestion that CRH signaling in our system is acting through
the CRHR1. It has been suggested that Ucn III plays a role in
high glucose-induced insulin secretion as blockage ofCRHR2
attenuates high (16.8 mM) but not low (10 mM) glucose-
induced insulin secretion from isolated rat islets in vitro (Li et al.
2006).Itispossiblealsothattheglucoseconcentration(10 mM)
usedinourstudywasnotoptimalforUcnIII-stimulatedinsulin
secretion, and that additional glucose dose–response and CRH
antagoniststudieswouldclarifytherespectiverolesofCRHand
Ucn III in insulin secretion from isolated mouse islets.
It is well known that AVP, through the AVPR1b, stimulates
ACTH secretion from anterior pituitary corticotropes and
potentiates the release of ACTH induced by CRH. CRH is
widely recognized as the primary factor maintaining basal HPA
activity and mediating the HPA axis response to acute stress.
However, studies have revealed that AVP and CRH are also
synthesized at low levels (compared with brain) in many other
tissuesincludingthepancreas(Hashimotoetal.1984,Sasakietal.
1987). For example, there is evidence that the rat adrenal
medulla contains a CRH-ACTH system, duplicating that
existing at the hypothalamic–pituitary level, which may be
involved in paracrine stimulation of glucocorticoid secretion
(Mazzochi et al.1 9 9 7 ). We speculated that AVP, acting through
the AVPR1b receptor, might modulate CRH-induced insulin
secretion in the endocrine pancreas. The present study
demonstratesthatAVPathighconcentrationsstimulatedinsulin
release from isolated mouse pancreatic islets, whereas at low
concentrations, which by themselves did not stimulate insulin
secretion, AVP potentiated CRH-induced insulin secretion
approximately threefold. This suggests a possible synergism
between AVP and CRH and indicates that AVP may be acting
on islet b-cells to increase their responsiveness to CRH. The
potentiating effect was only seen with subthreshold concen-
trations of AVP. If doses of AVP greater than the stimulus
threshold were used, then the process of insulin secretion
becameinsensitivetopotentiation.Itshouldbeemphasizedthat
the synergism seen between AVP and CRH on ACTH
secretion from pituitary corticotropes also occurs with
subthreshold concentrations of AVP (Yates et al.1 9 7 1 , Rivier
&V a l e1 9 8 3 ). Reduced availability of receptors (e.g. caused by
receptor internalization)orchangesinintracellulartransduction
processes may contribute to this desensitization. Our study on
pancreatic islets is the ﬁrst example of a possible interplay
between the AVP and CRH systems outside of the HPA axis.
We also demonstrate that the pancreatic AVP response is
speciﬁcfortheAVPR1b,asAVP-inducedandAVPpotentiation
of CRH-induced insulin secretion was completely absent in
micelackingfunctionalAVPR1breceptors.Assumingthatboth
AVP and CRH are acting directly on b-cells, and not acting
through some unknown intermediate, our results imply that
AVP1Rb and CRHR1/CRHR2 are co-localized in a
percentage of b-cells.
The speciﬁcityof the observed AVP/CRH potentiation was
investigated.Inthepituitary,CRH-stimulatedACTHsecretion
and cAMP accumulation are potentiated by PKC activators in
general (e.g. phorbol myristate acetate, PMA) and byactivation
of speciﬁc PKC-linked GPCRs such as AVPR1b and the
angiotensin II receptor (Abou-Samra et al.1 9 8 6 ). In the
pancreas, similar to AVP, agents such as acetylcholine have also
been shown to cause a PKC-dependent rise in intracellular
Ca
2C and to stimulate insulin secretion (Zawalich et al.2 0 0 4 ).
We investigated whether endogenously expressed receptors
(e.g. M3 and/or M1 muscarinic receptors) that activate PKC
also potentiate CRH-induced insulin secretion and found that
incubation of islets with CRH and a subthreshold dose of
carbachol, a cholinergic agonist, resulted in a greater than
twofold increase in CRH-induced insulin secretion. As the
potentiating effect of AVP can be imitated by carbachol, this
indicates a phenomenon that may be speciﬁc to the Ca
2C-
phospholipase C-signaling pathway, such as activation of PKC
or InsP3 production, or enhanced Ca
2C-inﬂux, rather than
speciﬁc for a certain agonist.
To determine whether this effect was mediated, in part or in
full, by the PKC pathway, isolated pancreatic islets were
preincubated in the presence or absence of either of two PKC
inhibitors, Ro-31-842 and Bis, prior to repeating the
potentiation studies. The 11 known PKC isozymes can be
divided into three major classes: the conventional (cPKC) that
areactivatedbybothCa
2Canddiacylglycerol(DAG);the novel
(nPKC) that require only DAG; and the atypical (aPKC) that
bind neither Ca
2C nor DAG. The PKC inhibitors Ro-31-842
and Bis show selectivity for cPKC and nPKC isozymes.
Preincubation with either PKC inhibitor attenuated the
potentiating effect of AVP on CRH-induced insulin secretion
to a non-potentiating level seen with CRH alone, while the
insulin-secreting effects of AVP alone were virtually abolished,
i.e., incubation with the PKC inhibitors removed the
potentiating effects seen with subthreshold doses of AVP.
These data suggest that, although low doses of AVP do not
stimulate insulin secretion, AVP potentiation of CRH-
stimulated insulin secretion appears to rely on PKC activation.
ThisstudysuggeststhatthepancreaticAVP/CRHpotentiation
is occurring intracellularly where the peptides may activate
signaling pathways anddownstream signalingmolecules suchas
cPKCandnPKC.Wecannotdiscountatthistimehoweverthat
effects occurring at the cell surface level, where either peptide
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also have a role to play.
Additionally, the possible interaction between PKC-depen-
dent (AVP) and PKA-dependent (CRH) signaling was
examined. Phorbol esters, such as PMA, can substitute for
DAG as high-afﬁnity ligands for cPKC and nPKC isoforms.
IncubationoftheisolatedpancreaticisletswithPMAstimulated
insulinsecretion,whiletheadditionofbothlowerdosesofPMA
and CRH enhanced insulin secretion over that measured after
theadditionofeitherPMAorCRHgivenalone,indicatingthat
both the PKA and PKC systems are involved in the observed
AVP potentiation of CRH-stimulated insulin secretion in
mousepancreaticislets.Thespeciﬁcityofthephorbolestereffect
wasdemonstratedbythelackofinsulinsecretionorpotentiation
of CRH-induced insulin secretion after incubation with the
inactive phorbol compound, 4-a-phorbol.
Experiments on the effects of extracellular Ca
2C on AVP
potentiation of CRH-induced secretion showed that poten-
tiation did not occur in the absence of extracellular Ca
2C,
suggesting that the interaction between AVP and CRH was
also critically dependent on Ca
2C inﬂux from the extracellu-
lar space. As a rise in cytosolic calcium is a critical trigger for
insulin release, measurements of cytosolic calcium done at the
level of both the whole islet and a single b-cell could provide
evidence as to whether the observed potentiating effect on
insulin secretion is dependent on the dynamics and levels of
intracellular Ca
2C within the b-cell.
The physiological relevance of AVP and CRH-induced
insulin secretion is unclear and assigning signiﬁcance to any
particularroleisspeculative.However,increasedAVPandCRH
levels are well-known correlates of stressful situations, and it is
possible that during some physiological and pathophysiological
situations (e.g. stress, pregnancy, adrenal deﬁciency, Cushing’s
syndrome, severe hemorrhage) elevated circulating plasma AVP
andCRHmaycontributetoincreasinginsulinsecretiontocope
withimmediatemetabolicdemands.Inaddition,thepresenceof
both AVP and CRH and their respective receptors in the
pancreatic b-islets supports a role for these peptides in the local
regulation of insulin secretion and the interplay between them
suggests a new intra-islet regulatory mechanism that adds an
additionallevelofcomplexitytomodulationofinsulinsecretion.
WhetherornotAVPpotentiatesCRHeffectsinotheraspectsof
pancreatic endocrine function, e.g. glucagon secretion and/or
b-cell growth and differentiation, remains to be determined.
In conclusion, in this study we have shown an interplay
between the AVP and CRH systems within the mouse
pancreas. AVP potentiated CRH-induced insulin secretion
from the isolated mouse pancreatic islets at concentrations
where, by itself, it failed to stimulate secretion, and this
potentiation was speciﬁc for the AVPR1b receptor subtype.
This interplay appeared to be mediated at least in part by the
PKC signaling pathway and was critically dependent on
extracellular Ca
2C. This observation supports the existence in
the pancreas of an in vivo synergism between these two
peptides, which is involved in paracrine or autocrine
stimulation of insulin secretion.
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